Lithuanian Pharmacy Market Consolidates as Five Major Chains Control 83% of Sales
Kaunas, Lithuania - A significant consolidation is underway in LithuaniaS pharmacy sector, with the five largest drug trading companies now controlling 83% of the market, according to a report published Tuesday by Verslo Žinios. This increasing dominance comes as smaller pharmacy networks continue to lose market share.
Combined revenue for patient medicines and beauty goods reached $1.125 billion (€1.05 billion) in 2023,with the top five players – Eurovaistinė,Nemunas pharmacy (including the Camelios network),amber pharmacy,Benu,and Norfos Pharmacy – accounting for the vast majority of sales. these networks collectively generated $1.3 billion in revenue in 2024, a 10% increase from the previous year, and earned $23.9 million,up 20.6% year-over-year.
Eurovaistinė, owned by Vilnius Prekyba, leads the market with $365.3 million in revenue for 2023. Nemunas pharmacy followed with $298.8 million, then Amber pharmacy at $246.2 million, Benu at $112.9 million, and norfos pharmacy at $101.9 million.
The trend coincides with a decline in the overall number of pharmacies operating in Lithuania. State medication control data shows 1,307 pharmacies were open in 2023, a decrease of 22 from the previous year and 78 fewer than in 2019. The Lithuanian Pharmacy Association reports a further reduction to 1,292 pharmacies currently operating – 15 fewer than in 2023.
This consolidation suggests a shifting landscape for pharmaceutical retail in lithuania, possibly impacting consumer choice and competition within the sector.
